Summary of Conference Call Records Industry Overview - The conference call primarily discusses the biopharmaceutical industry, focusing on several key companies and their projected performance for 2025 and beyond. The overall sentiment reflects a robust growth trajectory within the sector. Key Companies and Their Projections 1. WuXi AppTec (药明康德) - Expected revenue for 2025 is 454.56 billion CNY, a year-on-year increase of 15.84% - Adjusted net profit is projected to be 149.57 billion CNY, up 41.33%, with total net profit reaching 191.51 billion CNY, a 102.65% increase [2] - The company has 24 GLP-1 drug candidates, with 15 in Phase II and III clinical trials, indicating strong pipeline growth [4] 2. Kanglong Chemical (康龙化成) - Anticipates revenue between 138.72 billion CNY and 142.4 billion CNY, reflecting a growth of 13%-16% - Adjusted net profit is expected to be between 17.68 billion CNY and 18.48 billion CNY, a growth of 10%-15% [2] 3. Sunway Pharma (阳光诺和) - Projected revenue between 1.192 billion CNY and 1.37 billion CNY, a growth of 10.57%-27.15% - Expected net profit between 190 million CNY and 229 million CNY, a growth of 7.69%-29.23% [2] 4. AstraZeneca (阿斯利康) - Focused on cardiovascular, ADC, next-generation IO, and cell therapy TCE areas - Key clinical data readouts expected in 2026, which may impact market dynamics [5] 5. Gilead Sciences (吉利德) - Key projects include Cloud Native Top two ADC, expected to show promising data in TNBC treatment and potential approval in the second half of the year [8] - Anticipates significant changes in the first-line triple-negative breast cancer market due to the SG molecule [8] 6. DZD Pharma (迪哲医药) - DZD6,008 shows significant efficacy in non-small cell lung cancer (NSCLC) with an ORR of 60% and PFS exceeding 10 months [3][16] Clinical Trials and Data Readouts - Multiple companies, including Gilead, AstraZeneca, and others, are set to release important clinical trial data in 2026, which could reshape competitive dynamics in the NSCLC market [16] - AstraZeneca's ADC project 18.2 is expected to have significant clinical data readouts in 2026, with a focus on large-scale Phase III trials [7] Strategic Collaborations and Market Expansion - WuXi Biologics (药明生物) has signed a strategic cooperation memorandum with Qatar Free Zone Authority to expand into the Middle East market [4] - The conference highlighted the increasing participation of Chinese companies in the global pharmaceutical market, particularly in the dual-antibody and ADC sectors [22] Emerging Trends and Innovations - The industry is witnessing a shift towards L2.0 and ADC combinations, which are expected to become the next wave of drug development [17][18] - The importance of speed and mechanism synergy in new drug development was emphasized, indicating that early-stage projects have a higher success rate [18] Conclusion - The biopharmaceutical industry is poised for significant growth, with several companies reporting strong projections and innovative clinical developments. The upcoming clinical data releases in 2026 are anticipated to have a substantial impact on market dynamics and competitive positioning within the sector.

Core Viewpoint - The 44th J.P. Morgan Healthcare Conference highlighted the global pharmaceutical industry's focus on innovation, with HengRui Medicine showcasing its capabilities as a global pharmaceutical company from China, emphasizing platform-based R&D, business development (BD), and international clinical and registration systems [1][3]. Group 1: R&D and Innovation - HengRui has established a "dual-drive" model, investing over 25% annually in R&D and supporting a robust pipeline with over 100 new molecular entities (NMEs) and more than 400 clinical trials [3][4]. - The company’s "All-in Strategy" encompasses all major treatment modalities, including small molecules, large molecules, and peptides, demonstrating a comprehensive and iterative innovation engine [4][6]. - HengRui focuses on first-in-class (FIC) and best-in-class (BIC) therapies, with significant breakthroughs in challenging targets, such as the KRAS G12D inhibitor HRS-4642, which has shown a 63.3% objective response rate in clinical trials [6][7]. Group 2: Business Development and Internationalization - The trend at the conference indicated a shift towards BD as a mainstream strategy, with companies needing to demonstrate continuous innovation and stable delivery capabilities to attract investment [8][9]. - HengRui has completed 12 external licensing deals since 2023, valued at over $27 billion, showcasing its R&D strength and innovation quality recognized by top multinational corporations (MNCs) [12]. - The company is building a global capability system alongside its BD efforts, with significant progress in establishing R&D centers and teams, including a new center in Boston [13]. Group 3: Future Growth and Market Position - In 2026, HengRui is expected to achieve over 10 new drug approvals, submit more than 20 NDA/BLA applications, and report data from 25 Phase III studies, indicating a clear growth trajectory [14]. - The company anticipates a more than 25% year-on-year increase in innovative drug revenue, driven by the inclusion of 10 new products in the national medical insurance catalog [14]. - HengRui aims to enhance its global partnerships and accelerate international clinical trials, reflecting its commitment to a robust internationalization strategy [14][15].

Group 1 - Zhengzhou is focusing on digital transformation and industrial upgrading, leveraging its historical strength and vibrant economy to create a conducive environment for innovation and investment [2] - The city aims to build a new foundation for computing power and create new industrial clusters, while enhancing the business environment to attract quality resources and capital [2] - The collaboration with various enterprises is expected to foster innovation platforms, expand application scenarios, and share market benefits, contributing to the development of a smart economy and society [2][3] Group 2 - Guests expressed their admiration for Zhengzhou's cultural charm, innovative vitality, and industrial strength, indicating a strong potential for further cooperation in artificial intelligence and digital economy [3] - The focus will be on attracting new technologies, scientific innovation companies, and investment capital to support high-quality economic and social development in Zhengzhou [3]

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology industry [1]. Core Insights - The Chinese innovative drug sector has regained global attention, with over 20 Chinese pharmaceutical companies showcasing their advancements at the JPM 2026 conference. Notable companies like Heng Rui and BeiGene are expected to see significant revenue growth and product approvals in the coming years [4][17]. - The A-share pharmaceutical index has shown a year-to-date increase of 7.08%, outperforming the CSI 300 index by 4.88% [4][9]. - The report highlights specific sub-sectors within the industry, ranking them as follows: innovative drugs > research services > CXO > traditional Chinese medicine > medical devices > pharmacies [10]. Summary by Sections Industry Trends - The A-share pharmaceutical index has increased by 0.9% this week, with a year-to-date performance of 7.08%, while the Hang Seng Healthcare Index has risen by 15.63% [4][9]. - Medical services, raw materials, and medical devices have shown strong performance, with weekly increases of 5.63%, 1.70%, and 1.31%, respectively [4][9]. Company Highlights - Heng Rui is projected to achieve over 25% growth in innovative drug revenue in 2026, with multiple key drug approvals expected [17][18]. - BeiGene has solidified its position in hematological malignancies and is accelerating breakthroughs in solid tumors, with significant revenue growth reported [19]. Investment Recommendations - The report suggests focusing on specific companies based on their strengths in various therapeutic areas, including: - PD1 PLUS: Sangamo Therapeutics, CanSino Biologics, Innovent Biologics, and Zai Lab [13]. - ADC: I-Mab Biopharma, Kelun Pharmaceutical, and Bai Li Tianheng [13]. - Small nucleic acids: Frontier Biotechnologies, Fuyuan Pharmaceutical, and Yuyuan Pharmaceutical [13]. - Autoimmunity: Kangnuo Pharmaceutical, Yifang Biopharmaceutical, and Yipinhong [13]. - Leading innovative drug companies: BeiGene and Heng Rui [13]. - CXO and upstream research services: WuXi AppTec, Haoyuan Pharmaceutical, and Aopumai [13]. - Medical devices: United Imaging Healthcare and Yuyue Medical [13]. - AI drug development: Crystal Technology [13]. - GLP-1: Lianbang Pharmaceutical, Borui Pharmaceutical, and Zhongsheng Pharmaceutical [13]. - Traditional Chinese medicine: Zhaoli Pharmaceutical, Fangsheng Pharmaceutical, and Dong'e Ejiao [13].

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical sector [6][26]. Core Insights - The report emphasizes the continuous recommendation of innovative pharmaceuticals and medical devices, highlighting the high growth potential in the sector. It maintains "Overweight" ratings for companies such as Heng Rui Medicine, Hansoh Pharmaceutical, Sanofi, Kelun Pharmaceutical, and Enhua Pharmaceutical. It also recommends Biopharma/Biotech companies like Kelun Biotech, BeiGene, and others, as well as CXO and upstream pharmaceutical companies [6][3]. Summary by Sections 1. Continuous Recommendation of Innovative Pharmaceuticals and Medical Devices - The report highlights the high growth potential of innovative drugs and recommends several companies for investment, including Heng Rui Medicine, Hansoh Pharmaceutical, Sanofi, Kelun Pharmaceutical, and Enhua Pharmaceutical. It also suggests Biopharma/Biotech companies like Kelun Biotech, BeiGene, and others, as well as CXO and upstream pharmaceutical companies [6][7]. 2. A-share Pharmaceutical Sector Performance - In the third week of January 2026, the A-share pharmaceutical sector underperformed the broader market, with the Shanghai Composite Index declining by 0.4% and the SW Pharmaceutical and Biotech index falling by 0.7% [8][11]. 3. Hong Kong and US Market Performance - The Hong Kong pharmaceutical sector performed in line with the market, while the US pharmaceutical sector underperformed. In the same week, the Hang Seng Healthcare index rose by 2.4%, and the S&P 500 healthcare sector fell by 1.1% [19][20].

Core Insights - The 44th J.P. Morgan Healthcare Conference highlighted the global pharmaceutical industry's focus on innovation and the search for next-generation pipelines, with HengRui Pharma presenting its global strategy and capabilities [1][2]. Group 1: Company Strategy and Development - HengRui Pharma has established a "dual-engine" model, investing over 25% of its annual revenue in R&D, which supports its position as the second-largest in global original drug pipelines [2]. - The company is advancing its internationalization through flexible BD collaborations and a solid overseas team, aiming to accelerate the realization of innovative value [2][3]. - HengRui's R&D framework includes over 100 new molecular entities (NMEs) and more than 400 clinical trials across key therapeutic areas such as oncology, cardiovascular, metabolism, immunology, and neuroscience [3][7]. Group 2: Innovation and Pipeline - HengRui's pipeline is structured to provide comprehensive solutions in critical disease areas, focusing on synergy, iterative innovation, and addressing unmet medical needs [7]. - The company has demonstrated breakthrough capabilities in challenging targets, such as the KRAS G12D inhibitor HRS-4642, which has shown a 63.3% objective response rate in clinical trials [8]. - In the metabolic disease sector, HengRui is targeting the $100 billion obesity market with its GLP-1 asset portfolio, including the dual agonist HRS9531, which has shown significant weight loss results in clinical trials [8]. Group 3: Business Development and Internationalization - Since 2023, HengRui has completed 12 licensing deals worth over $27 billion, securing $1.3 billion in cash and equity investments, showcasing its R&D strength and innovation quality [12]. - The company aims to push approximately 20 new molecular entities into clinical trials annually, indicating a robust and efficient R&D pipeline [9][12]. - HengRui's internationalization strategy includes establishing a global capability system, with 15 R&D centers and a team of over 5,600, enhancing its global presence and operational capacity [13]. Group 4: Future Outlook - In 2026, HengRui is expected to achieve significant milestones, including over 10 new drug approvals and more than 20 NDA/BLA submissions, with key data from its pipeline assets anticipated [14]. - The company projects a revenue growth of over 25% year-on-year from its innovative drugs, supported by new products entering the national medical insurance directory [15]. - HengRui is committed to becoming a global leader in pharmaceuticals, focusing on delivering innovative drugs to patients worldwide, reflecting the broader trend of Chinese innovation in the pharmaceutical industry [16].

Group 1 - Recent star companies in technology, consumer, and high-end manufacturing sectors are driving market momentum, enhancing the linkage between capital markets in both regions [1] - Notable A-share companies are making significant progress in their listings in Hong Kong, including Longqi Technology, which is currently in the process of going public and has attracted investments from major institutions [2] - Dongpeng Beverage has successfully passed the listing hearing in Hong Kong and has maintained a leading market share in China's functional beverage market, increasing from 15% in 2021 to 26.3% in 2024 [2] Group 2 - The AH premium index has shown slight fluctuations, reflecting a recent increase in A-share performance compared to H-shares, with the index reported at 120.43 points as of January 16, up from 115.44 points at the end of the previous year [6] - The recent trend of A-share companies listing in Hong Kong has led to a decrease in the AH premium index, as high-quality A-share companies enhance liquidity in the Hong Kong market [6] - Currently, there are 37 companies with an AH premium exceeding 100%, with Zhejiang Shibao leading at a premium rate of 360.30% [7] Group 3 - Multiple factors are contributing to the current trend of A-share companies listing in Hong Kong, including a stronger A-share market driven by high-tech sectors, while the Hong Kong market remains influenced by traditional sectors [8] - The liquidity situation in the A-share market, supported by long-term capital allocations and individual investors leveraging, contrasts with the Hong Kong market, which is affected by external risk preferences [8] - The Hong Kong IPO market is expected to remain active in 2026, with a significant number of companies in the pipeline, including 105 A-share projects [9]

Core Viewpoint - Heng Rui Medicine's subsidiary has received approval for clinical trials of HRS-7535, a new oral small molecule GLP-1 receptor agonist, marking its entry into the weight loss drug market, which is currently dominated by injectable GLP-1 drugs [4][6]. Group 1: Product Overview - HRS-7535 is an innovative oral small molecule GLP-1 receptor agonist that does not rely on injection, addressing the challenges of achieving sufficient receptor activation and safety in oral administration [6]. - The mechanism of HRS-7535 includes promoting insulin secretion, inhibiting glucagon release, delaying gastric emptying, and enhancing satiety through the central nervous system, making it suitable for treating type 2 diabetes and weight loss [6]. Group 2: Market Positioning - The global weight loss drug market is currently dominated by injectable peptides that achieve weight loss of 15%-25%, but they face issues related to compliance, production costs, and long-term use burdens [7]. - Oral small molecule GLP-1 is viewed as a potential disruptive innovation; if it can balance efficacy and safety, its accessibility and commercialization potential will significantly increase [7]. Group 3: Industry Implications - The approval of HRS-7535 for clinical trials indicates a strategic shift among leading domestic innovative pharmaceutical companies, moving from merely following injectable peptide competition to seeking differentiated breakthroughs in small molecules and oral formulations [8]. - The development of oral small molecule GLP-1 is highly challenging, and while clinical risks are significant, successful outcomes could have strategic value and industry impact that far exceed the product itself [8].

Core Insights - The J.P. Morgan Healthcare Conference highlighted the weight loss market as a key focus, with major pharmaceutical companies like Eli Lilly, Novo Nordisk, and Pfizer emphasizing their commitment to this sector [1] - Pfizer plans to launch weight loss assets acquired from Metzera by mid-2028, indicating a long-term strategy in the weight loss market [1] - Eli Lilly's Orforglipron has been submitted for approval in China, following its inclusion in the FDA's expedited approval list in November 2025 [1] Pricing Strategies - Novo Nordisk announced a significantly lower price for its oral version of semaglutide (Wegovy) compared to its injectable counterpart, with monthly costs starting at approximately $149 for self-paying patients [2] - The price of injectable semaglutide (Ozempic) was previously set at $969 per month, while Wegovy was priced at $1,349 per month [2] - Agreements with the U.S. government will lead to price reductions for semaglutide and Orforglipron starting in 2026, with some products capped at $50 per month [3] Market Competition - The GLP-1 market is experiencing intense competition, with 88 small molecule GLP-1 drugs currently in development, including six in Phase III trials [3] - A price war has erupted in the GLP-1 injection market, driven by increased supply and the expiration of patents for key products [4] - The introduction of new competitors and the expansion of indications for GLP-1 drugs are reshaping the market landscape [5] Domestic Market Dynamics - The new national medical insurance directory in China has initiated a price competition era for GLP-1 products, with significant discounts being offered on e-commerce platforms [4][6] - The price of semaglutide and other competing products has seen drastic reductions, with some prices dropping to as low as 20% of their original costs [5][6] - The entry of multiple domestic companies into the GLP-1 market is intensifying the price competition, particularly as patents expire [9][19] Future Outlook - The GLP-1 market is expected to grow significantly, with projections indicating a potential market size exceeding $100 billion by 2030 [16] - The competition is shifting from price-based to innovation-based, focusing on multi-target therapies and expanded indications [16] - The expiration of key patents is likely to lead to an influx of generic competitors, further intensifying the price competition [17][19]

Core Viewpoint - The Hong Kong stock market in 2025 is characterized by a "dual-driven" capital active state of "IPO + refinancing," with both segments experiencing significant recovery, raising a total of 285.6 billion HKD in IPOs and 273.5 billion HKD in refinancing, indicating equal importance in the competition for underwriting strength in the Hong Kong equity financing market [1][7]. Group 1: Market Overview - The total IPO fundraising in the Hong Kong market reached 285.6 billion HKD as of January 16, 2026, while refinancing (including convertible bonds) amounted to 273.5 billion HKD, showing a balanced financing scale [1][7]. - The competition among major players such as CITIC, CICC, Morgan Stanley, and Goldman Sachs has led to distinct competitive paths, with domestic institutions focusing on the IPO track and foreign institutions concentrating on the refinancing track [1][7]. Group 2: Major Players and Their Strategies - CITIC Securities led the underwriting market with a total underwriting scale of 90.1 billion HKD, including 57.8 billion HKD in IPOs and 32.3 billion HKD in refinancing [2][8]. - Morgan Stanley achieved a total underwriting scale of 62.9 billion HKD, with nearly equal contributions from IPOs (30.8 billion HKD) and refinancing (32.2 billion HKD), making it one of the few firms excelling in both areas [3][9]. - Goldman Sachs focused heavily on the refinancing sector, leading with an underwriting scale of 43 billion HKD, primarily through large projects like BYD and Xiaomi, while only participating in 8 IPOs throughout the year [5][11]. Group 3: Project Highlights - Morgan Stanley's top IPO projects included Zijin Mining International (28.7 billion HKD), Hengrui Medicine (11.4 billion HKD), and Haitian Flavoring & Food (10.6 billion HKD) [4][10]. - Goldman Sachs' notable refinancing projects included BYD (43.5 billion HKD) and Xiaomi (42.6 billion HKD), which accounted for 90% of its refinancing scale [6][12].